Future-Proof Your Pipeline: B2B Lead Generation Strategies for the AI Era AI-powered lead generation transforms B2B pipelines with precision targeting, predictive analytics, and personalized outreach. Intent Amplify™ delivers future-proof strategies that convert high-intent leads at scale. Your Next Big Deal Starts Here! Connect with us and explore data-driven B2B marketing solutions. @ https://rb.gy/cfmwba

The Ultimate Guide to Omnichannel Lead Generation for B2B Success Omnichannel B2B lead generation, powered by AI, integrates diverse channels for consistent, personalized engagement. Intent Amplify uses data-driven strategies for targeted, optimized outreach, driving qualified conversions. Supercharge Your Sales Pipeline with AI-Powered Lead Generation @ https://rb.gy/5oymgt

Oil & Gas Pipeline Inspection Market: Emerging Technologies & Growth 2032 View Full Report : https://dataintelo.com/report/global-oil-and-gas-pipeline-inspection-service-market The global oil and gas pipeline inspection service market is witnessing significant growth, driven by increasing demand for energy, rising safety concerns, and stringent regulatory policies. With aging pipeline infrastructure and the surge in exploration and production activities, the need for advanced inspection solutions has never been greater. According to DataIntelo,the global oil and gas pipeline inspection service market size was valued at USD 3.2 billion in 2023 and is projected to reach USD 5.8 billion by 2032, exhibiting a CAGR of 6.5% during the forecast period. The adoption of smart inspection technologies, such as drones, robotics, and AI-driven analytics, is expected to play a crucial role in enhancing operational efficiency and ensuring pipeline integrity.

#Oil_Country_Tubular_Goods (OCTG) refers to a class of steel pipes used in the exploration and production of oil and gas. These pipes play a crucial role in drilling, well completion, and hydrocarbon extraction. Read More: https://wemarketresearch.com/reports/oil-country-tubular-goods-market/1213 #OCTG #OilCountryTubularGoods #OilAndGas #EnergyIndustry #Drilling #Casing #Tubing #SteelPipes #Oilfield #WellCompletion #Petroleum #NaturalGas #UpstreamEnergy #OilfieldServices #EnergySector #Pipeline

Oil Pipeline Cleaning Service Market Demand, Manufacturer, Report to 2032 In this report published by DataIntelo, we analyse the major drivers and challenges for this market with an emphasis on macroeconomic trends in each region. We also provide our readers with insights into how these factors are affecting both regional markets and individual companies within the Oil Pipeline Cleaning Service industry. Claim your Sample Copy of this Report: https://dataintelo.com/request-sample/?reportId=598416

Oil and Gas Pipes Market, Overview, Growth, Analysis And Regional Forecast Of by Fact MR The global oil and gas pipes market (石油およびガスパイプ市場) stands at US$ 66.2 billion in 2023. Worldwide demand for oil and gas pipes is projected to increase at a CAGR of 6.7% and reach a market value of US$ 127 billion by the end of 2033. The global Oil and Gas Pipes Market is a critical component of the energy industry, providing the essential infrastructure for the extraction, transportation, and distribution of hydrocarbons. These pipes serve as the veins of the industry, enabling the movement of crude oil and natural gas from production sites to processing facilities, refineries, and end-users across the world. The market for oil and gas pipes is influenced by a complex interplay of factors, including technological advancements, geopolitical dynamics, environmental concerns, and economic fluctuations. Get FREE Sample Copy of Report (Including TOC, List of Tables & Figures, Chart) @https://www.factmr.com/connectus/sample?flag=S&rep_id=8797 Report Attributes Details Oil and Gas Pipes Market Size (2022) US$ 62 Billion Estimated Market Value (2023) US$ 66.2 Billion Forecasted Market Value (2033) US$ 127 Billion Global Market Growth Rate (2023 to 2033) 6.7% CAGR Stainless Steel Segment Growth Rate (2023 to 2033) 7.5% CAGR Key Companies Profiled Chevron Corporation ConocoPhillips Company BP PLC China National Petroleum Corporation (CNPC) Borealis AG Baker Hughes Company American Cast Iron Pipe Company China Steel Corporation (CSC) American Piping Products ArcelorMittal SA Arabian Pipes Company Chemical Process Piping Pvt. Ltd. Abu Dhabi Metal Pipes & Profiles Industries Complex LLC CEF Group China Metallurgical Information and Standardization Institute The demand for oil and gas pipes is closely tied to the overall health of the energy sector. As the world's population continues to grow, so does the demand for energy, especially in developing countries. This drives the need for increased exploration and production of oil and gas, subsequently boosting the demand for pipes. Additionally, advancements in drilling technologies have opened up previously inaccessible reserves, further propelling the need for efficient and reliable pipeline networks. The type of pipes used in the oil and gas industry varies based on the specific application. Steel pipes, including carbon steel, stainless steel, and alloy steel, are the most common due to their durability and strength. Flexible pipes, made from polymers and composites, are also gaining traction, particularly in offshore applications where corrosion resistance and flexibility are crucial. However, these materials come with their own challenges, including cost and compatibility with the transported fluids. Geopolitical factors play a significant role in shaping the oil and gas pipes market. Oil and gas are often extracted in politically unstable regions, leading to potential supply disruptions and price volatility. Pipelines that traverse multiple countries also require international cooperation and agreement, making geopolitical relationships a critical consideration in pipeline planning and construction. Environmental concerns have added a layer of complexity to the industry. The transportation of oil and gas through pipelines has generally been considered safer and more environmentally friendly than other modes like tankers or trucks. However, pipeline leaks and accidents can have devastating consequences for ecosystems and communities. As a result, regulatory bodies have tightened safety standards, leading to increased investments in pipeline integrity monitoring and maintenance technologies. Economic factors, including oil and gas prices, influence investment decisions in new pipeline projects. When prices are high, there is a greater incentive to invest in exploration and production, driving the demand for pipelines. Conversely, low prices can lead to project delays or cancellations. Moreover, the cost of pipeline construction itself is a significant factor. Lengthy pipelines, especially those crossing challenging terrains like mountains or oceans, require substantial capital investment. In recent years, technological innovations have been reshaping the oil and gas pipes market. The integration of sensors, data analytics, and automation has led to the development of "smart pipelines." These pipelines can monitor conditions in real-time, detecting leaks, corrosion, or other issues early on and allowing for prompt maintenance. This not only enhances safety but also improves the efficiency of operations. Another trend is the exploration of alternative energy sources and the growing push for a transition to cleaner fuels. While this shift might lead to a reduced demand for traditional oil and gas pipelines in the long run, it also presents opportunities. Many oil and gas companies are diversifying their portfolios to include renewable energy sources like hydrogen or biomethane. This could lead to repurposing existing pipeline infrastructure or developing new pipelines for these emerging energy carriers. Get Customization on this Report for Specific Research Solutions:https://www.factmr.com/connectus/sample?flag=RC&rep_id=8797 Conclusion the oil and gas pipes market remains a vital component of the global energy landscape. Its dynamics are influenced by a multitude of factors, ranging from technological advancements to geopolitical tensions and environmental concerns. As the world continues to seek a balance between energy demand and environmental sustainability, the market will likely undergo significant changes. These changes will require industry players to adapt, innovate, and invest in order to meet the evolving needs of the energy sector while ensuring the safety and sustainability of their operations. More Details Industrial Related Report Portable Air Compressor Market-(ポータブルエアコンプレッサー市場) https://www.factmr.com/report/4511/portable-air-compressor-market Europe Loader Blades Market-(ヨーロッパのローダーブレード市場) https://www.factmr.com/report/europe-loader-blades-market Plasterboard Market-(石膏ボード市場) https://www.factmr.com/report/plasterboard-market Spray Drying Equipment Market-(噴霧乾燥装置市場) https://www.factmr.com/report/4418/spray-drying-equipment-market About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, industrial goods to even the most niche categories. 80% of Fortune 1000s trust us in critical decision making. Contact: US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E-Mail: sales@factmr.com

Exosome Therapeutics market Growth Analysis and Forecast by 2035 Roots Analysis has done a detailed study on Exosome Therapeutics Market, 2022-2040, covering key aspects of the industry and identifying future growth opportunities Key Market Insights  Close to 60 players, worldwide, have taken initiatives to develop exosome therapeutics; the market is characterized by the presence of start-ups and small companies  The current pipeline features more than 120 exosome therapeutics that are being evaluated across different phases of development; most of these are designed for intravenous administration  3,000+ patients have been recruited / enrolled in clinical trials evaluating exosome related therapies and biomarkers across different geographies  More than 530 grants have been awarded for the ongoing R&D efforts for exosome therapeutics; University of California has been awarded the maximum grant amount of USD 21 million  A variety of investors, having realized the benefits and future opportunities in this field, have invested more than USD 570 million across more than 30 instances, since 2017  The rising interest of stakeholders in exosome therapeutics is also reflected by the increasing number of partnerships established by various industry and non-industry players  Stakeholders have participated in various global events to discuss the research outcomes, and affiliated challenges as well as opportunities existing in this domain  At present, more than 30 start-ups are driving innovation in this domain; a variety of R&D initiatives have been undertaken by these players over the last few years for the development of exosome therapeutics  Lack of efficacy, COVID-19 pandemic, limited patient enrollment, and scarce funding are among the key reasons that have led to the discontinuation of studies sponsored by various industry and non-industry players  With the rising demand for therapeutic advances in drug safety, the market of exosome therapeutics is expected to grow at an annualized rate of 41% between 2029-2040  The projected market opportunity is likely to be well distributed across different routes of administration, types of formulations and key geographical regions Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Market Segmentation 1.3. Research Methodology 1.4. Key Questions Answered 1.5. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Overview of Exosomes 3.1.1. Types of Extracellular Vesicles 3.1.1. Potential Sources of Exosomes 3.2. Exosome Biogenesis 3.2.1. Exosome Formation and Development Process 3.2.2. Secretion of Exosomes 3.3. Applications of Exosomes 3.4. Mechanism of Exosome Therapy 3.4.1. Exosome Drug Therapy 3.4.2. Exosome RNAi Therapy 3.4.3. Exosome Immunotherapy 3.5. Advantages of Exosome Therapies 3.6. Risks and Future Perspectives Associated with Exosome Therapeutics 4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE 4.1. Analysis Methodology and Key Parameters 4.2. Exosome Therapeutics Market Landscape 4.2.1. Analysis by Phase of Development 4.2.2. Analysis by Technology Platform 4.2.3. Analysis by Type of Payload 4.2.4. Analysis by Derived Source 4.2.5. Analysis by Target Disease Indication(s) 4.2.6. Analysis by Therapeutic Area 4.2.7. Analysis by Phase of Development and Therapeutic Area 4.2.8. Analysis by Therapeutic Area and Route of Administration 4.2.9. Analysis by Route of Administration 4.2.10 Analysis by Area of Application 4.2.11. Analysis by Type of Therapy 4.2.12. Analysis by Dosing Frequency 4.2.13. Analysis by Type of Therapy (By Method of Composition) 4.2.14. Analysis by Line of Treatment 4.3. Exosome Therapeutics Developers 4.3.1. Analysis by Year of Establishment 4.3.2. Analysis by Company Size 4.3.3. Analysis by Location of Headquarters 4.3.4. Most Active Players: Analysis by Number of Therapeutics 5. EXOSOME THERAPEUTICS DEVELOPERS: COMPANY PROFILES 5.1. Coya Therapeutics 5.1.1. Company Overview 5.1.2. Product Portfolio 5.1.3. Recent Developments and Future Outlook 5.2. Codiak BioSciences 5.3.1. Company Overview 5.3.2. Product Portfolio 5.3.3. Clinical Trial Information 5.3.4. Recent Developments and Future Outlook 5.4. Evox Therapeutics 5.4.1. Company Overview 5.4.2. Product Portfolio 5.4.3. Recent Developments and Future Outlook 5.5. Curexsys 5.5.1. Company Overview 5.5.2. Product Portfolio 5.5.3. Recent Developments and Future Outlook 5.6. EV Therapeutics 5.6.1. Company Overview 5.6.2. Product Portfolio 5.6.3. Recent Developments and Future Outlook 5.7. SHIFTBIO 5.7.1. Company Overview 5.7.2. Product Portfolio 5.7.3. Recent Developments and Future Outlook 6. EXOSOME THERAPEUTICS: DRUG PROFILES 6.1. AEGLE Therapeutics 6.1.1. Company Overview 6.1.2. AGLE-102: Product Portfolio 6.1.2.1. AGLE-102: Clinical Trial Information 6.1.3. Recent Developments and Future Outlook 6.2. AVEM Healthcare 6.2.1. Company Overview 6.2.2. Ardoxso: Product Portfolio 6.2.2.1. Ardoxso: Clinical Trial Information 6.2.3. Recent Developments and Future Outlook 6.3. Cellular Biomedicine Group 6.3.1. Company Overview 6.3.2. Financial Information 6.3.3. haMPC-Exos: Product Portfolio 6.3.3.1. haMPC-Exos: Clinical Trial Information 6.3.4. hMSC-Exos: Product Portfolio 6.3.4.1. hMSC-Exos: Clinical Trial Information 6.3.5. Undisclosed Drug 1: Product Portfolio 6.3.5.1. Undisclosed Drug 1: Clinical Trial Information 6.3.6. Recent Developments and Future Outlook 6.4. OBCTCD24 6.4.1. Company Overview 6.4.2. CovenD24: Product Portfolio 6.4.2.1. CovenD24: Clinical Trial Information 6.4.3. Recent Developments and Future Outlook 6.5. ReNeuron 6.5.1. Company Overview 6.5.2. Financial Information 6.5.3. Undisclosed Drug 1: Product Portfolio 6.5.3.1. Undisclosed Drug 1: Clinical Trial Information 6.5.4. Recent Developments and Future Outlook 6.6. Stem Cell Medicine 6.6.1. Company Overview 6.6.2. Undisclosed Drug 1: Product Portfolio 6.6.3. Recent Developments and Future Outlook 7. CLINICAL TRIAL ANALYSIS 7.1. Analysis Methodology and Key Parameters 7.2. Exosome Therapeutics: List of Clinical Trials 7.2.1. Analysis by Trial Status 7.2.2. Analysis by Trial Registration Year 7.2.3. Analysis by Sponsor / Collaborator 7.2.4. Analysis by Trial Registration Year and Type of Study 7.2.5. Analysis by Trial Registration Year and Trial Status 7.2.6. Analysis by Annual Number of Patients Enrolled 7.2.7. Analysis by Study Design 7.2.8. Analysis by Age Category 7.2.9. Analysis by Phase of Development and Trial Status 7.2.10. Analysis by Phase of Development and Patients Enrolled 7.2.11. Most Active Industry Players: Analysis by Number of Registered Trials 7.2.12. Most Active Non-Industry Players: Analysis by Number of Registered Trials 7.2.13. Analysis by Trial Location 7.2.14. Analysis by Trial Status and Geography 7.2.15. Analysis by Trial Status, Patients Enrolled and Geography 8. ACADEMIC GRANT ANALYSIS 8.1. Analysis Methodology and Key Parameters 8.2. Exosome Therapeutics: List of Academic Grants 8.3. Analysis by Year of Grants Awarded 8.4. Analysis by Amount Awarded per Year 8.5. Analysis by Type of Funding Institute Center 8.6. Analysis by Support Period 8.7. Analysis by Purpose of Grant 8.8. Word Cloud Analysis: Emerging Focus Area 8.9. Analysis by Grant Activity Code 8.10. Analysis by Location of Recipient Organizations 8.11. Popular Recipient Organizations: Analysis by Number of Grants 8.12. Popular Recipient Organizations: Analysis by Amount Awarded 8.13. Analysis by Type of Recipient Organization 8.14. Analysis by Study Section 8.15. Analysis by Type of Grant Application 8.16. Analysis by Funding Institute Center and Support Year 9. GLOBAL EVENT ANALYSIS 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. List of Global Events Related to Exosomes 9.3.1. Analysis by Year of Event 9.3.2. Analysis by Event Platform 9.3.3. Analysis by Type of Event 9.3.4. Analysis by Region 9.3.5. Most Active Organizers: Analysis by Number of Events 9.3.6. Most Active Speakers: Analysis by Number of Events 9.3.7. Most Active Industry Participants: Analysis by Number of Events 9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events 9.3.9. Analysis by Designation of Participant 9.3.10. Analysis by Affiliated Department of Participant 9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area 10. PARTNERSHIPS AND COLLABORATIONS 10.1. Chapter Overview 10.2. Partnership Models 10.3. Exosome Therapeutics: List of Partnerships and Collaborations 10.3.1. Analysis by Year of Partnership 10.3.2. Analysis by Type of Partnership 10.3.3. Analysis by Year and Type of Partnership 10.3.4. Analysis by Company and Type of Partnership 10.3.5. Analysis by Type of Technology Platform 10.3.6. Analysis by Type of Partner 10.3.7. Most Active Players: Analysis by Number of Partnerships 10.3.8. Word Cloud Analysis: Emerging Focus Areas 10.3.9. Analysis by Target Disease Indication(s) 10.3.10.Analysis by Therapeutic Area 10.3.11.Analysis by Therapeutic Area and Type of Partnership 10.3.12. Regional Distribution of Partnerships 10.3.13. Distribution by Geography 11. FUNDING AND INVESTMENT ANALYSIS 11.1. Analysis Methodology and Key Parameters 11.2. Type of Funding 11.3. Exosome Therapeutics: List of Funding Instances 11.4. Analysis by Year of Funding 11.5. Analysis by Amount Invested 11.6. Analysis by Type of Funding 11.7. Analysis by Type of Funding and Amount Invested 11.8. Analysis by Purpose of Funding 11.9. Analysis by Target Disease Indication(s) 11.10. Analysis by Therapeutic Area 11.11. Most Active Players: Analysis by Number of Funding Instances 11.12. Most Active Players: Analysis by Amount Raised 11.13. Active Investors: Analysis by Number of Funding Instances 11.14. Distribution by Geography 11.15. Summary of Funding Activity 12. START-UP HEALTH INDEXING 12.1. Analysis Methodology and Key Parameters 12.2. Analysis by Pipeline Strength 12.3. Analysis by Pipeline Maturity 12.4. Analysis by Indication Diversity 12.5. Analysis by Number of Partnerships 12.6. Analysis by Financial Support 12.7. Start-up Health Indexing: Roots Analysis Perspective 12.8. Most Active Start-ups 13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS 13.1. Chapter Overview 13.2. Exosome Development and Manufacturing Service Providers Landscape 13.2.1. Analysis by Year of Establishment 13.2.2. Analysis by Company Size 13.2.3. Analysis by Location of Headquarters 13.2.4. Analysis by Location of Headquarters and Company Size 13.3. Analysis by Type of Service(s) Offered 13.3.1. Analysis by Method of Isolation 13.3.2. Analysis by Method of Purification 13.3.3. Analysis by Method of Characterization 13.3.4. Analysis by Method of Exosome Manufacturing 13.3.5. Analysis by Scale of Operation 13.3.6. Analysis by Scalability 14. DRUG FAILURE ANALYSIS 14.1. Methodology and Key Parameters 14.2. Exosome Therapeutics: List of Failed Drug Candidates 14.2.1. Analysis by Trial Start and Discontinuation Year 14.2.2. Analysis by Trial Status of Discontinuation 14.2.3. Analysis by Target Disease Indication(s) 14.2.4. Analysis by Route of Administration 14.2.5. Analysis by Type of Sponsor 14.2.6. Analysis by Reasons for Drug Failure 14.2.7. Word Cloud Analysis: Emerging Focus Area 15. MARKET SIZING AND OPPORTUNITY ANALYSIS 15.1. Forecast Methodology and Key Assumptions 15.2. Global Exosome Therapeutics Market, 2029-2040 15.2.1. Exosome Therapeutics Market for Allogeneic Therapy, 2029-2040 (USD Million) 15.2.2. Exosome Therapeutics Market for Autologous Therapy, 2029-2040 (USD Million) 15.2.3. Exosome Therapeutics Market for Degenerative Meniscal Injury, 2031-2040 (USD Million) 15.2.4. Exosome Therapeutics Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million) 15.2.5. Exosome Therapeutics Market for Fistula Perianal, 2029-2040 (USD Million) 15.2.6. Exosome Therapeutics Market for Retinitis Pigmentosa, 2029-2040 (USD Million) 15.2.7. Exosome Therapeutics Market for Dermatological Disorders, 2030-2040 (USD Million) 15.2.8. Exosome Therapeutics Market for Muscoskeletal Disorders, 2031-2040 (USD Million) 15.2.9. Exosome Therapeutics Market for Ophthalmic Disorders, 2029-2040 (USD Million) 15.2.10. Exosome Therapeutics Market for Rectal Disorders, 2029-2040 (USD Million) 15.2.11. Fistula Tract Exosome Therapeutics Market, 2029-2040 (USD Million) 15.2.12. Intra-articular Exosome Therapeutics Market, 2031-2040 (USD Million) 15.2.13. Intra-ocular Exosome Therapeutics Market, 2029-2040 (USD Million) 15.2.14. Exosome Therapeutics Market Geographical Distribution, 2029-2040 (USD Million) 15.2.15. Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million) 15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million) 15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million) 15.2.18. Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million) 15.2.19. ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million) 16. EXECUTIVE INSIGHTS 16.1. Capricor Therapeutics 16.1.1. Company Snapshot 16.1.2. Interview Transcript: Xavier Avat, Chief Business Officer 16.2. Exogenus Therapeutics 16.2.1. Company Snapshot 16.2.2. Interview Transcript: Patricia C. Freire, R&D and Innovation Manager 16.3. ILIAS Biologics 16.3.1. Company Snapshot 16.3.2. Interview Transcript: Soonho Song, Chief Business Officer 17. APPENDIX 1: TABULATED DATA 18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To view more details on this report, click on the link https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html You may also be interested in the following titles: Lab Automation Market Cannabis Testing Market You may also like to learn what our experts are sharing in Roots educational series: Antiviral Drugs Development: Are we Prepared for the Next Viral Pandemic? Exploring How Artificial Intelligence Is Transforming Digital Pathology About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #ExosomeTherapeuticsMarketTrends #ExosomeTherapeuticsMarketGrowth #exosometherapies #MSCderivedexosomes #Extracellularvesicles

Novel Antibody Therapies market Research Report by 2022, Forecast till 2035 Roots Analysis has done a detailed study on Novel Antibody Therapies Market covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights  Presently, around 55 players across the globe are engaged in developing novel antibody therapies for the treatment of multiple disease indications; majority of large players are based in North America  Currently, majority of the radioimmunoconjugates are in clinical stages of development; more than 50% of the microbial immunotoxin candidates are administrated intravenously  Several big pharma players have undertaken a variety of initiatives for novel antibodies, ranging from proprietary product development to patent filing  550+ clinical trials related to novel antibody therapies have been registered till date; majority (44%) of these trials were / are being conducted across various clinical sites based in Europe  Over the past few years, more than 570 articles related to novel antibody therapies have been published by several eminent authors in high-impact journals; more than 50% of the articles were published in 2021  Since 2017, more than 4,600 patents have been granted / filed for various novel antibody therapies, demonstrating the rising interest and rapid pace of research in this field  The growing interest in this field is evident from the rise in partnership activity form the year 2020; a major proportion of the deals were signed by companies based in North America  With the rising demand for new therapeutic modalities with high efficacy, the novel antibody therapies market is likely to grow at a steady pace till 2035  The opportunity associated with novel antibody therapies market is likely to be well distributed across various types of therapies, route of administration and key geographical regions Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2 Market Segmentation 1.3. Research Methodology 1.4. Key Questions Answered 1.5. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Overview of Novel Antibody Therapies 3.2. Types of Novel Antibody Therapies 3.2.1. Antibody-Directed Enzyme Prodrug Therapy (ADEPT) 3.2.1.1. Mechanism of Action of ADEPT 3.2.1.2. Advantages of ADEPT 3.2.1.3. Disadvantages of ADEPT 3.2.2. TCR like Antibodies 3.2.2.1. Mechanism of Action of TCR like Antibodies 3.2.2.2. Advantages of TCR like Antibodies 3.2.2.3. Disadvantages of TCR like Antibodies 3.2.3. Radioisotope Immunoconjugates 3.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates 3.2.3.2. Advantages of Radioisotope Immunoconjugates 3.2.3.3. Disadvantages of Radioisotope Immunoconjugates 3.2.4. Immunotoxins 3.2.4.1. Mechanism of Action of Immunotoxins 3.2.4.2. Advantages of Immunotoxins 3.2.4.3. Disadvantages of Immunotoxins 3.2.5. Intracellular Antibody 3.2.5.1. Mechanism of Action of Intracellular Antibody 3.2.5.2. Advantages of Intracellular Antibody 3.2.5.3. Disadvantages of Intracellular Antibody 3.2.6. Immunocytokines 3.2.6.1. Mechanism of Action of Immunocytokines 3.2.6.2. Advantages of Immunocytokines 3.2.6.3. Disadvantages of Immunocytokines 3.3. Therapeutic Antibodies: Development Approaches 3.4. Future Perspectives 4. NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE 4.1. Analysis Methodology and Key Parameters 4.2. Novel Antibody Therapies: Development Pipeline (Immunocytokines) 4.2.1. Analysis by Status of Development 4.2.2. Analysis by Mechanism of Action 4.2.3. Analysis by Type of Cytokine 4.2.4. Analysis by Status of Development and Type of Cytokine 4.2.5. Analysis by Type of Antigen / Format 4.2.6. Analysis by Dosing Frequency 4.2.7. Analysis by Type of Therapy 4.2.8. Analysis by Mode of Administration 4.2.9. Analysis by Route of Administration 4.2.10. Analysis by Target Disease Indication(s) 4.3. Novel Antibody Therapies: Development Pipeline (Immunotoxins) 4.3.1. Analysis by Status of Development 4.3.2. Analysis by Mechanism of Action 4.3.3. Analysis by Type of Toxin 4.3.4. Analysis by Dosing Frequency 4.3.5. Analysis by Type of Therapy 4.3.6. Analysis by Mode of Administration 4.3.7. Analysis by Immunotoxin Target 4.3.8. Analysis by Special Drug Designation 4.3.9. Analysis by Route of Administration 4.3.10. Analysis by Target Disease Indication(s) 4.4. Novel Antibody Therapies: Development Pipeline (Radioisotope Immunoconjugates) 4.4.1. Analysis by Status of Development 4.4.2. Analysis by Type of Radioisotopes 4.4.3. Analysis by Status of Development and Type of Radioisotopes 4.4.4. Analysis by Route of Administration 4.4.5. Analysis by Type of Therapy 4.4.6. Analysis by Dosing Frequency 4.4.7. Analysis by Mode of Administration 4.4.8. Analysis by Special Drug Designation 4.4.9. Analysis by Target Disease Indication(s) 4.5. Novel Antibody Therapies: Development Pipeline (Other Antibodies) 4.6. Novel Antibody Therapies: List of Developers 4.6.1. Analysis by Type of Player 4.6.2. Analysis by Company Size 4.6.3. Analysis by Year of Establishment 4.6.4. Analysis by Location of Headquarters (Region-wise) 4.6.5. Analysis by Location of Headquarters (Country-wise) 4.6.6. Analysis by Company Size and Region of Headquarters 4.6.7. Leading Players: Analysis by Number of Therapeutics 5. COMPANY PROFILES 5.1. Actinium Pharmaceuticals 5.1.1. Company Overview 5.1.2. Financial Information 5.1.3. Product Portfolio 5.1.4. Recent Developments and Future Outlook 5.2. Molecular Templates 5.2.1. Company Overview 5.2.2. Financial Information 5.2.3. Product Portfolio 5.2.4. Recent Developments and Future Outlook 5.3. Philogen 5.3.1. Company Overview 5.3.2. Financial Information 5.3.3. Product Portfolio 5.3.4. Recent Developments and Future Outlook 5.4. Roche 5.4.1. Company Overview 5.4.2. Financial Information 5.4.3. Product Portfolio 5.4.4. Recent Developments and Future Outlook 5.5. Seagen 5.5.1. Company Overview 5.5.2. Financial Information 5.5.3. Product Portfolio 5.5.4. Recent Developments and Future Outlook 5.6. Sesen bio 5.6.1. Company Overview 5.6.2. Financial Information 5.6.3. Product Portfolio 5.6.4. Recent Developments and Future Outlook 5.7. Telix Pharmaceuticals 5.7.1. Company Overview 5.7.2. Financial Information 5.7.3. Product Portfolio 5.7.4. Recent Developments and Future Outlook 5.8. Y-mAbs Therapeutics 5.8.1. Company Overview 5.8.2. Financial Information 5.8.3. Product Portfolio 5.8.4. Recent Developments and Future Outlook 6. CLINICAL TRIAL ANALYSIS 6.1. Analysis Methodology and Key Parameters 6.2. List of Clinical Trials Focused on Novel Antibody Therapies 6.2.1. Analysis by Trial Status 6.2.2. Analysis by Trial Registration Year 6.2.3. Analysis by Trial Registration Year and Trial Status 6.2.4. Analysis by Trial Phase 6.2.5. Analysis by Trial Phase and Patients Enrolled 6.2.6. Analysis by Trial Registration Year and Patients Enrolled 6.2.7. Analysis by Type of Sponsor / Collaborator 6.2.8. Analysis by Disease Indication(s) 6.2.9. Analysis by Study Design 6.2.10. Most Active Industry Players: Analysis by Number of Trials 6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials 6.2.12. Analysis by Type of Treatment 6.2.13. Analysis by Type of Drug 6.2.14. Word Cloud Analysis: Emerging Focus Areas 6.2.15. Analysis by Top Indication(s) and Trial Phase 6.2.16. Analysis by Top Indication(s) and Leading Industry Players 6.2.17. Analysis by Trial Location 6.2.18. Analysis by Geography and Trial Status 7. PUBLICATION ANALYSIS 7.1. Analysis Methodology and Key Parameters 7.2. List of Publications Focused on Novel Antibody Therapies 7.2.1. Analysis by Year of Publication 7.2.2. Word Cloud Analysis: Emerging Focus Areas 7.2.3. Analysis by Type of Article 7.2.4. Top Authors: Analysis by Number of Publications 7.2.5. Key Journals: Analysis by Number of Publications 7.2.6. Key Journals: Analysis by Impact Factor 7.2.7. Most Popular Publishers: Analysis by Number of Publications 7.2.8. Most Popular Copyright Holders: Analysis by Number of Publications 8. PATENT ANALYSIS 8.1. Analysis Methodology and Key Parameters 8.2. List of Patents Focused on Novel Antibody Therapies 8.2.1. Analysis by Patent Publication Year 8.2.2. Year-wise Trend of Granted Patents 8.2.3. Analysis by Type of Patent 8.2.4. Analysis by Granted Patents and Patent Applications 8.2.5. Analysis by Geography 8.2.6. Analysis by CPC Symbols 8.2.7. Analysis by Type of Applicant 8.2.8. Analysis by Patent Age 8.2.9. Word Cloud Analysis: Emerging Focus Areas 8.2.10. Leading Industry Players: Analysis by Number of Patents 8.2.11. Leading Non-Industry Players: Analysis by Number of Patents 8.2.12. Leading Individual Assignees: Analysis by Number of Patents 8.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols) 8.2.14. Patent Valuation: Analysis Methodology and Parameters 8.2.15. Patent Valuation: Analysis by Relative Valuation 9. PARTNERSHIPS AND COLLABORATIONS 9.1. List of Partnerships and Collaborations Focused on Novel Antibody Therapies 9.1.1. Analysis by Year of Partnership 9.1.2. Analysis by Type of Partnership 9.1.3. Analysis by Year and Type of Partnership 9.1.4. Most Popular Drug: Analysis by Number of Partnerships 9.1.5. Analysis by Types of Novel Antibodies 9.1.6. Analysis by Target Disease Indication(s) 9.1.7. Analysis by Type of Partnership and Target Indication(s) 9.1.8. Analysis by Type of Partner 9.1.9. Most Active Players: Analysis by Number of Partnerships 9.1.10. Most Active Players: Analysis by Type of Partnership 9.1.11. Regional Analysis of Partnerships 9.1.12. Intercontinental and Intracontinental Agreements 10. BIG PHARMA PLAYERS 10.1 Analysis Methodology and Key Parameters 10.2. Scoring Criteria for Key Parameters 10.3. List of Big Pharma Players Focused on Novel Antibody Therapies 10.3.1. Analysis by Supplier Strength 10.3.2. Analysis by Portfolio Strength 10.3.3. Analysis by Portfolio Diversity 10.3.4. Benchmarking: Spider Web Analysis 10.3.5. Benchmarking: Harvey Ball Analysis 10.3.6. Benchmarking: Wind Rose Chart 11. MARKET SIZING AND OPPORTUNITY ANALYSIS 11.1. Forecast Methodology and Key Assumptions 11.2. Global Novel Antibody Therapies Market, 2022-2035 11.3. Product-wise Sales Forecast (Marketed Drugs) 11.3.1. Adcetris (Seagen) 11.3.1.2. Sales Forecast 11.3.2. Elzonris (Menarini Group) 11.3.2.2. Sales Forecast 11.3.3. Pluvicto (Novartis) 11.3.3.2. Sales Forecast 11.4. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Novel Antibodies 11.4.1 Novel Antibody Therapies Market for Immunocytokines, 2024-2035 11.4.2 Novel Antibody Therapies Market for Immunotoxin, 2023-2035 11.4.3 Novel Antibody Therapies Market for Radioisotope Immunoconjugates, 2023-2035 11.5. Global Novel Antibody Therapies Market, 2026 and 2035: Distribution by Target Disease Indication(s) 11.5.1 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2023-2035 11.5.2 Novel Antibody Therapies Market for Bladder Cancer, 2023-2035 11.5.3 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2025-2035 11.5.4 Novel Antibody Therapies Market for Graft-versus-host disease, 2026-2035 11.5.5 Novel Antibody Therapies Market for Melanoma, 2024-2035 11.5.6 Novel Antibody Therapies Market for Prostate Cancer, 2026-2035 11.5.7 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2025-2035 11.6. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Therapy 11.6.1. Novel Antibody Therapies Market for Combination Therapy, 2024-2035 11.6.2. Novel Antibody Therapies Market for Monotherapy, 2023-2035 11.7. Global Novel Antibody Therapies Market, 2023 and 2035: Distribution by Route of Administration 11.7.1. Novel Antibody Therapies Market for Intratumoral Drugs, 2023-2035 11.7.2. Novel Antibody Therapies Market for Intravenous Drugs, 2023-2035 11.7.3. Novel Antibody Therapies Market for Intravesical Drugs, 2023-2035 11.8. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Geography 11.8.1. Novel Antibody Therapies Market in North America, 2023-2035 11.8.2. Novel Antibody Therapies Market in Europe, 2025-2035 11.8.3. Novel Antibody Therapies Market in Asia Pacific, 2023-2035 11.9. Product-wise Sales Forecast (Phase III Drugs) 11.9.1. Adcetris (Seagen) 11.9.1.1. Target Patient Population 11.9.1.2. Sales Forecast 11.9.1.3. Net Present Value 11.9.1.4. Value Creation Analysis 11.9.2. Fibromun (Philogen) 11.9.2.1. Target Patient Population 11.9.2.2. Sales Forecast 11.9.2.3. Net Present Value 11.9.2.4. Value Creation Analysis 11.9.3. Iomab-B (Actinium Pharmaceuticals) 11.9.3.1. Target Patient Population 11.9.3.2. Sales Forecast 11.9.3.3. Net Present Value 11.9.3.4. Value Creation Analysis 11.9.4. Nidlegy (Philogen) 11.9.4.1. Target Patient Population 11.9.4.2. Sales Forecast 11.9.4.3. Net Present Value 11.9.4.4. Value Creation Analysis 11.9.5. T-Guard (Xenikos) 11.9.5.1. Target Patient Population 11.9.5.2. Sales Forecast 11.9.5.3. Net Present Value 11.9.5.4. Value Creation Analysis 11.9.6. TLX 591 (Telix Pharmaceuticals) 11.9.6.1. Target Patient Population 11.9.6.2. Sales Forecast 11.9.6.3. Net Present Value 11.9.6.4. Value Creation Analysis 11.9.7. Vicinium (Sesen Bio) 11.9.7.1. Target Patient Population 11.9.7.2. Sales Forecast 11.9.7.3. Net Present Value 11.9.7.4. Value Creation Analysis 12. APPENDIX 1: TABULATED DATA 13. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/novel-antibody-therapies-market.html You may also be interested in the following titles: Cell Therapy Manufacturing Market Global TCR Therapy Market You may also like to learn what our experts are sharing in Roots educational series: Is Blue Ocean Strategy The Silver Bullet For Emerging Teleradiology Players to Achieve A Breakthrough In This Highly Competitive Market? CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #NovelAntibodyTherapiesMarket #NovelAntibodyTherapiesMarketGrowth #NovelAntibodyTherapies #intrabodies #novelantibodies